Samsrita Labs Share Price

Samsrita Labs Limited was initially established as Dr Habeebullah Life Sciences Limited on January 25, 1996. The name of the Company was changed from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited on October 13, 2022. Company, initially focused on three different verticals called, Stem cell related Hospitals, Molecular Diagnostics and RD in New Drug Discovery but due to other reasons, aimed to shifting into Biopharma activities like Trading, Exports Imports, manufacturing of Bulk drugs, APIs, Specialty drugs, RD etc through joint ventures or associations or mergers or by its own. The Company is engaged into the business of research experimental development on natural sciences and engineering, including bio pharma and hospital services also.In 2017, the Company changed its Main Objects clauses by venturing into the business of BioPharma and also entered the following areas like New Drug Discovery including New Molecular Entity (NME Pro Drug) Clinical Research Organization (CRO) related activities Stem Cell Lab, Research and Therapy Research and Development in Biotechnology Consultancy Division and Pharmacy Academic Services like Courses / Lectures / Seminars on Biotechnology, Pharma, Stem Cell Research and therapy, Clinical Research and animal studies etc. Nutraceuticals product development Trading, exporting and importing of medicinal drugs, chemicals, reagents etc.In 201617, the Company entered into a Collaborative Agreement with Krisani Bio Sciences Private Limited for further development of NASH (Fatty Liver) Molecule and Wilson Disease Molecule on revenue sharing basis and also entered into a Collaborative Agreement with Centre For liver Research And Diagnostics (CLRD) to use their land , building, equipment and other facilities to run their business of Hospital, Diagnostics, Pharmacy, Stem cell and other biotechnology laboratories on revenue sharing basis. A diversified healthcare company with innovation is at the forefront of research and development in stem cells regenerative medicine, new drug discovery, RNAi therapeutics, biomarker discovery. The Company was named after late Dr.CM Habeebullah, whose dedication and passion form the backbone of the Companys core values to provide affordable, world class cutting edge healthcare facilities to all. The Company has been established as an advanced center for research and excellence in areas of Stem Cell RD and Therapy, New Drug discovery, Molecular Diagnostics, Stem cell based multi Specialty Hospital and CRO.Krisani Bio Sciences Private Limited ceased to be the subsidiary of the Company with effect from 12.11.2021 and was made an Associate Company because of allotment of 64,00,000 equity shares at Rs. 10/ each by Krisani Bio Sciences Private Limited, erstwhile Subsidiary of the Company on a preferential basis and as a result the shareholding of the Company in Krisani Bio Sciences Private Limited came down from 51.33% to 32.91% in 2022.During year 202425, the Board of Directors in the meeting held on 30.04.2025, altered the objects of the company by adding a new subclause including engaging in biofuels, food industry including processing, seeds, Green technologies, Information technology including deep technologies, logistics, ecommerce, Clinical research and allied activities and advisory services.

For the full year FY2023–2024, revenue reached ₹0.31 crore and profit touched at ₹-0.26 crore.